Influence of phytocorrection on the oppression of the processes of benign prostatic hyperplasia in patients with concomitant chronic inflammatory diseases of the prostate

##plugins.themes.bootstrap3.article.sidebar##

PDF (Українська)
DOI: https://doi.org/10.30841/2307-5090.1(56).2016.95426
Keywords:
chronic prostatitis, benign prostatic hyperplasia, phytotherapy, Pravenor®,

##plugins.themes.bootstrap3.article.main##

І. І. Горпинченко
ДУ «Інститут урології НАМН України», м. Київ, Ukraine
Ю. М. Гурженко
ДУ «Інститут урології НАМН України», Ukraine
В. В. Спиридоненко
ДУ «Інститут урології НАМН України», Ukraine

Abstract

The article deals with the aspects of conservative therapy of chronic prostatitis (CP) and benign prostatic hyperplasia (BPH) by using a combination of herbal substances. In the SI «Institute of Urology of NAMS of Ukraine» were observed 127 patients with CP and minimally complicated BPH of the I degree, who were divided into three clinical groups. Group I (n=43) consisted of patients who received Pravenor® 2 capsules per day after meals for a period of one year. Group II (n=52) comprised of patients who received standard monotherapy with tamsulosin 4 mg per day. In the III group (n=32) are included patients who did not receive treatment during the investigation period. Control group (IV) (n=30) is included almost healthy men (mean age 32,4±0.5 years). The age of patients ranged from 49 to 63.5 years (mean age of 54,0±1.2 years). The average history of the disease CP is 12.8±1.3 years, BPH 2,8±0,3 years. It was found that conservative therapy of patients with CP and initial symptoms of BPH requires the use of plant inhibitors of 5A-reductase. The combination of herbal ingredients (Pravenor®) on the background of CP and BPH of I degree is reliably effective and require treatment for more than 6 months. Pravenor® is able to stable a possible recovery of IPSS and QoL in persons with minimally complicated BPH, taking the drug for more than 6 months.

##plugins.themes.bootstrap3.article.details##

How to Cite
Горпинченко, І. І., Гурженко, Ю. М., & Спиридоненко, В. В. (2016). Influence of phytocorrection on the oppression of the processes of benign prostatic hyperplasia in patients with concomitant chronic inflammatory diseases of the prostate. Health of Man, (1(56), 121–126. https://doi.org/10.30841/2307-5090.1(56).2016.95426
Issue
No. 1(56) (2016)
Section
Urology
Copyright (c) 2020 І. І. Горпинченко, Ю. М. Гурженко, В. В. Спиридоненко

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.

Author Biographies

І. І. Горпинченко, ДУ «Інститут урології НАМН України», м. Київ

I. I. Gorpynchenko

Ю. М. Гурженко, ДУ «Інститут урології НАМН України»

Y. N. Gurzhenko

В. В. Спиридоненко, ДУ «Інститут урології НАМН України»

V. V. Spiridonenko

References

Baltaci S., Orhan D., Cogus C., Turkolmez K., et al. Inducible nitric oxide synthase expression in BPH, low and high grade PIN and prostate carcinoma // BJU Int. – 2001 – V. 88 – P. 100–103.

Basler J.W., Piazza G.A. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention // J Urol. – 2004. – V. 171. – P. 59–S63.

Berges R.R., Pientka L., Hufner K. et al. Male lower urinary tract symptoms and related health care seeking in Germany // Eur. Urology. – 2001 – Vol. 39. – P. 682.

Bostanci Y., Kazzazi A., Momtahen S., Laze J., Djavan В. Correlation between benign prostatic hyperplasia and inflammation // BENIGN PROSTATIC HYPERPLASIA. – 2013 – Vol. 23 (1). – Р. 5–10.

Chua T., Eise N.T, Simpson J.S., Ventura S. Pharmacological characterization and chemical fractionation of a liposterolic extract of saw palmetto (Serenoa repens): effects on rat prostate contractility //J Ethnopharmacol. – 2014 Mar 14. – V. 152 (2). – P. 283–91.

De Marzo A.M., Platz E.A., Sutcliffe S. et al. Inflammation in prostate carcinogenesis // Nat Rev. – 2007. – V. 7. – P. 256–269.

De Marzo A.M. Pathological and molecular mechanisms of prostate cancerogenesis: implications for diagnosis, prevention and treatment // J Cell Biochem. – 2004. – V. 91. – P. 459–477.

De Marzo A.M., Marchi V.L., Epstein J.I., Nelson W.G. Proliferative inflammatory atrophy of the prostate // Am. J.Pathol. – 1999. – V. 155. – P. 1985–1992.

Dennis L., Lynch C.F., Tornes J.C. Epidemiologic association between prostatitis and prostate cancer // Urology. – 2002. – V. 60. – P. 78–83.

Di Silverio F., Bosman C., Salvatori M. et al. Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) // Eur. Urol. – 2005. – V. 47 – P. 72–79.

Di Silverio F, Gentile V., De Matteis A., et al. Distribution of inflammation, premalignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis // Eur Urol. – 2003. – V. 43. – P. 164–175.

Djavan B. Lower urinary tract symptoms benign prostatic hyperplasia: fast control of the patient’s quality of life //Urology. – 2003 Sep;62(3 Suppl 1). – P. 6–14.

Drachenberg C.B., Papadimitriou J.C. Prostatic corpora amylacea and crystalloids: similarities and differences on ultrastructural and histochemical studies // J Submicroscop Cytol Pathol. – 1996. – V. 28. – P. 141–150.

Elkahwaji J.E., Zhong W., Bushman W. Chronic bacterial infection and inflammation incite reactive hyperplasia in a mouse model of chronic prostatitis // Prostate. – 2007. – V. 67. – P. 14–21.

Ficarra V, Rossanese M, Zazzara M et. al. The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy//Curr Urol Rep. 2014. Dec;15 (12): P. 463.

Forray C., Bard J.A., Wetzel J.M. et al. The б1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human б1с subtype. Mol. Pharmacol. 1994; 45 (4): 703–708.

Goldstraw M.A., Fitzpatrick J.M., Kirby R.S. What is the role of inflammation in the pathogenesis of prostate cancer // BJU Int. – 2007. – V. 15. – P. 1–2.

Gradini R., Realacci M., Petrangeli E., Di Silverio F., Russo M. Nitric oxide synthases in normal and benign hyperplastic human prostate: immunohistochemistry and molecular biology // J. Pathol. – 1999 –V. 189. –P. 224–229.

Irani J., Levillian P., Gouion J.M., Bon D., et al. Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value // J Urol. – 1997. – V. 157. – P. 1301–1303

Karakiewicz P.I., Benayoun S., Begin L.R. et al. Chronic inflammation is negatively associated with prostate cancer and high grade prostatic intraepithelial neoplasia on needle biopsy // Int J Clin Pract. – 2007. – V. 71. – P. 425–430.

Kramer G., Mitteregger D., Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? // Eur Urol. – 2007. – V. 51. – P. 1202–1216.

Lowe F., Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia// Curr. Opin. Urol. – 2002. – Vol. 12. – P. 15.